Mounjaro for Heart Failure: Off-Label Use, Evidence, and What Women Need to Know

What "Off-Label" Means for Tirzepatide and Heart Failure

Tirzepatide is not FDA-approved to treat heart failure. Full stop. When a clinician prescribes Mounjaro for a woman with heart failure, that is an off-label decision, meaning the prescriber is acting on clinical evidence and judgment rather than an approved label indication.

The FDA approved tirzepatide (Mounjaro) for type 2 diabetes in May 2022 and approved the higher-dose formulation (Zepbound) for chronic weight management in November 2023 for adults with a BMI <30 kg/m² plus a weight-related comorbidity, or BMI <27 with comorbidities. Heart failure is not listed in either label.

Off-label prescribing is legal and common in cardiology and internal medicine. The question is whether the evidence is strong enough to justify the tradeoffs for a specific woman at a specific life stage.

Why Clinicians Are Interested

Tirzepatide is a dual GIP and GLP-1 receptor agonist. Beyond glucose and weight, it reduces inflammation, lowers blood pressure, improves lipid profiles, and reduces visceral adiposity, all of which matter in heart failure with preserved ejection fraction (HFpEF). HFpEF is the dominant heart failure phenotype in women, particularly after menopause.

What GRADE Says About the Evidence

Using the GRADE framework, the evidence for tirzepatide in HFpEF currently sits at:

• Symptom improvement and exercise capacity: Moderate certainty
• Reduction in worsening HF events: Moderate certainty (driven largely by one large trial)
• Cardiovascular mortality reduction: Low certainty (SUMMIT was not powered for mortality alone)
• HFrEF (reduced ejection fraction): Very low certainty (no large dedicated trial yet)

This is worth knowing before you and your clinician weigh in.

The SUMMIT Trial: The Best Evidence Available

The SUMMIT trial is the most important piece of evidence for tirzepatide in heart failure. Published in the New England Journal of Medicine in 2024, SUMMIT enrolled 731 adults with obesity-related HFpEF (heart failure with preserved ejection fraction, defined as ejection fraction <50%, NYHA class II-IV symptoms, and BMI <30 kg/m²).

Participants received tirzepatide up to 15 mg weekly or placebo for 52 weeks. The primary endpoint was a composite of worsening heart failure events or cardiovascular death.

Key results:

• Tirzepatide reduced the primary composite endpoint by 38% compared with placebo (hazard ratio 0.62, 95% CI 0.41 to 0.95)
• The 6-minute walk test distance improved by a mean of 18.3 meters more in the tirzepatide group
• Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score improved by 6.9 points more with tirzepatide, a clinically meaningful difference
• Body weight fell by approximately 13.6% in the tirzepatide arm versus 2.5% with placebo

The trial did not show a statistically significant reduction in cardiovascular mortality on its own. This is a meaningful limitation when counseling patients about the difference between feeling better and living longer.

Women in SUMMIT

Approximately 51% of SUMMIT participants were women, which is better representation than many cardiology trials historically provide. women have been systematically under-enrolled in heart failure trials for decades, and sex-stratified subgroup analyses from SUMMIT have not yet been published in full. The overall findings are promising, but we cannot yet say with certainty whether the magnitude of benefit differs by sex. This is an honest evidence gap.

Why Heart Failure in Women Is Different

HFpEF is often called a "women's disease" because women account for roughly 55 to 60% of HFpEF cases. This matters for understanding who might benefit most from tirzepatide off-label.

The Hormonal Connection

Estrogen has cardioprotective effects. During the reproductive years, premenopausal women have lower rates of heart failure than men of the same age. After menopause, that protection drops sharply.

The 2024 ACC/AHA joint statement on cardiovascular disease in women explicitly notes that the menopausal transition accelerates visceral fat accumulation, insulin resistance, and hypertension, all major drivers of HFpEF. A woman in perimenopause may find herself developing metabolic HFpEF at a time when she is already managing hot flashes, sleep disruption, and mood changes. This overlap is clinically real and underappreciated.

Tirzepatide's ability to reduce visceral adiposity and improve insulin sensitivity is therefore particularly relevant to perimenopausal and postmenopausal women developing obesity-related HFpEF.

HFpEF vs HFrEF: The Evidence Gap Matters More for Women

Most heart failure drug trials historically enrolled patients with heart failure with reduced ejection fraction (HFrEF), and HFrEF populations skew male. Women with HFrEF exist, but HFpEF is the pattern more likely to bring a woman to your cardiologist's office after 50.

Right now, tirzepatide has solid trial data only in HFpEF. There is no large published trial of tirzepatide in HFrEF. If your ejection fraction is below 40%, using Mounjaro for heart failure would be based on mechanistic reasoning and very limited observational data, not a randomized controlled trial. Your clinician should be transparent about that distinction.

Life-Stage Breakdown: How Heart Failure and Tirzepatide Interact Across a Woman&apos;s Life

Reproductive Years (Ages 18-40)

Heart failure in younger women is uncommon but not rare. Causes include peripartum cardiomyopathy, congenital heart disease, chemotherapy-related cardiomyopathy, and autoimmune myocarditis. Obesity-related HFpEF in this age group is rising as obesity rates climb.

Tirzepatide off-label for heart failure in reproductive-age women requires a serious contraception conversation first. See the pregnancy section below.

Perimenopause (Typically Ages 45-55)

This is the highest-risk window for developing new HFpEF related to hormonal and metabolic shifts. The Menopause Society's 2023 position statement acknowledges that cardiovascular risk rises during the menopausal transition and that weight gain, insulin resistance, and hypertension frequently cluster in this period.

A practical clinical framework for perimenopausal women presenting with both obesity and new HFpEF might consider tirzepatide as the metabolic anchor because it addresses weight, insulin resistance, and potentially cardiac remodeling simultaneously, rather than treating each problem with a separate drug. This is a clinical hypothesis rather than guideline-endorsed practice, and your cardiologist and internist should make this decision together.

Post-Menopause (Ages 55 and Beyond)

The SUMMIT trial population was predominantly in this age range. Post-menopausal women with HFpEF, obesity, and either type 2 diabetes or prediabetes are the group for whom the evidence is most directly applicable, even off-label.

Drug interactions become more complex in this group. Many post-menopausal women with HFpEF are already on diuretics, ACE inhibitors or ARBs, SGLT2 inhibitors, and beta-blockers. Tirzepatide's GLP-1 activity can slow gastric emptying, which may affect oral medication absorption timing. Your pharmacist can help sequence medications to minimize this effect.

Risks and Tradeoffs You Should Know

Tirzepatide is not benign. Every off-label use requires an honest risk-benefit analysis.

Common Side Effects

• Nausea, vomiting, diarrhea, constipation: reported in up to 40-50% of users in the SURMOUNT trials at therapeutic doses
• These are usually dose-dependent and most intense during dose escalation
• For a woman with heart failure, severe vomiting raises the risk of dehydration, which can destabilize volume status acutely

Heart Failure-Specific Concerns

Heart failure management depends heavily on fluid balance. Starting tirzepatide in someone with compensated heart failure requires close monitoring:

• GI fluid losses from nausea and vomiting can cause hypovolemia in a patient on diuretics
• Rapid weight loss from fat and fluid may require diuretic dose adjustments within weeks
• Blood pressure reduction (tirzepatide lowers systolic BP by an average of approximately 6-8 mmHg in trials) may allow dose reduction of antihypertensives but also risks symptomatic hypotension

Less Common but Serious Risks

• Pancreatitis: Rare but reported. Women with a history of gallstones (which are more common in women, particularly after rapid weight loss) face elevated risk. The FDA label carries a warning for pancreatitis.
• Thyroid C-cell tumors: Seen in rodent studies; relevance to humans is uncertain. The FDA label includes a boxed warning and recommends against use in patients with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2.
• Gallbladder disease: Rapid weight loss increases gallstone formation risk. Women already have a two-fold higher baseline gallstone risk than men.
• Hypoglycemia: Mainly a risk when combined with insulin or sulfonylureas, not when used alone.

Monitoring Recommendations for Women on Tirzepatide for Heart Failure

| Parameter | Frequency | |---|---| | Body weight | Every 2-4 weeks initially | | Blood pressure | Every visit; home monitoring daily during titration | | Serum electrolytes and renal function | Every 4-8 weeks initially, especially if on diuretics | | Diuretic dose review | At each weight-change assessment | | GI symptom severity | Every 2 weeks during dose escalation | | HbA1c (if diabetic) | Every 3 months | | Lipase if abdominal symptoms | As clinically indicated |

Who This Is Right For, and Who Should Avoid It

Most Likely to Benefit

• Post-menopausal women with HFpEF, BMI <30 kg/m², and obesity-driven metabolic disease (meets SUMMIT criteria most closely)
• Women with HFpEF who also have type 2 diabetes or prediabetes (dual indication overlap)
• Women with HFpEF who have not achieved adequate symptom control with standard therapy (SGLT2 inhibitors, diuretics, blood pressure control)
• Perimenopausal women with early HFpEF and significant visceral adiposity where weight-directed therapy is a priority

Should Approach with Caution or Avoid

• Women with active or history of medullary thyroid carcinoma or MEN2 (boxed warning contraindication)
• Women with active gallbladder disease or prior pancreatitis
• Women who are pregnant or planning pregnancy within 2 months (see section below)
• Women with HFrEF (reduced ejection fraction): evidence is insufficient; discuss with your cardiologist
• Women with severe gastroparesis: tirzepatide worsens gastric motility further
• Women on multiple hypoglycemic agents where hypoglycemia risk is already elevated
• Women with NYHA class IV heart failure not yet stabilized: starting a new medication during acute decompensation is inappropriate

PCOS, Metabolic Syndrome, and the HFpEF Connection

Women with PCOS have a 2 to 3-fold higher risk of insulin resistance and metabolic syndrome, which are direct precursors to HFpEF. A 2022 analysis in the Journal of Clinical Endocrinology and Metabolism found that women with PCOS have significantly elevated rates of cardiovascular risk factors compared to age-matched controls.

Tirzepatide's ability to reduce insulin resistance makes it potentially attractive for women with PCOS who are also developing early cardiac risk markers. This is speculative and not guideline-endorsed, but it reflects the biological overlap between these conditions. If you have PCOS and your cardiologist is considering tirzepatide for early HFpEF signs, the metabolic benefit could serve double duty. That conversation is worth having.

Pregnancy, Lactation, and Contraception

Tirzepatide is contraindicated in pregnancy. This is not a soft recommendation. Animal studies show fetal harm at doses below human therapeutic levels. There are no adequate human pregnancy safety data. The FDA prescribing information for Zepbound/Mounjaro advises discontinuing tirzepatide at least 2 months before a planned pregnancy because of the drug's long half-life (approximately 5 days, but full clearance takes longer).

For women of reproductive age prescribed tirzepatide off-label for heart failure:

• Use highly effective contraception throughout treatment
• Options include IUDs (hormonal or copper), progestin implants, or tubal ligation
• If a pregnancy occurs while on tirzepatide, stop the drug immediately and contact your cardiologist and OB-GYN within 24 hours
• Pregnancy itself carries substantial cardiac risk in women with heart failure; pre-conception counseling with a maternal-fetal medicine specialist is strongly recommended before attempting to conceive if you have HFpEF

Lactation: It is not known whether tirzepatide is excreted in human breast milk. Animal studies show presence in milk. The FDA label recommends against use during breastfeeding given potential infant risk and the availability of alternative approaches for managing heart failure in postpartum women.

Postpartum: Peripartum cardiomyopathy (PPCM) is a specific postpartum cardiac condition affecting roughly 1 in 1,000 to 1 in 4,000 deliveries in the US, with higher rates in Black women. If you are a postpartum woman being evaluated for heart failure, tirzepatide is not appropriate while breastfeeding, and even after weaning, the primary management of PPCM involves bromocriptine, ACE inhibitors, and beta-blockers rather than GLP-1 agents. Tirzepatide has no established role in PPCM currently.

The Honest Evidence Gap

Women have been under-enrolled in cardiovascular trials for decades. A 2020 analysis in JAMA Cardiology found that women represented only 25.8% of participants in heart failure trials between 2014 and 2019, despite making up the majority of HFpEF patients. SUMMIT did better than average, but we are still extrapolating some findings.

Sex-specific pharmacokinetic data for tirzepatide are limited. Women generally have lower body weight, lower renal clearance, and different fat distribution patterns than men, all of which can affect drug exposure. A population pharmacokinetic analysis of semaglutide, a related GLP-1 agent, found that women had approximately 25% higher drug exposure at the same dose compared with men. Similar analyses for tirzepatide in women have not been published in peer-reviewed form. This means the dose-response and side-effect profile you experience may differ from what trial averages suggest.

The field is moving fast. The HEART-HF trial (tirzepatide in HFrEF) and additional analyses from SUMMIT are expected to add clarity over the next two years. Until then, any use of Mounjaro for heart failure is genuinely off-label and requires a well-informed consent discussion.

How Tirzepatide Compares to Other Agents in HFpEF

Women with HFpEF now have one guideline-recommended drug class that specifically addresses this phenotype: SGLT2 inhibitors. The 2022 AHA/ACC/HFSA Heart Failure Guideline gives SGLT2 inhibitors a Class 2a recommendation for HFpEF for reducing hospitalizations, based on the EMPEROR-Preserved and DELIVER trials.

Tirzepatide is not in the guidelines. It sits in a different category: a potentially additive metabolic intervention that addresses root causes (obesity, insulin resistance, inflammation) rather than serving as a primary HF-specific drug. Thinking of it as complementary to, rather than replacing, your SGLT2 inhibitor is probably closer to how most cardiologists would frame it in 2025.

The cost question is real too. Mounjaro runs approximately $1,000 to $1,200 per month without insurance coverage for off-label use. Insurance coverage for heart failure as an indication is essentially non-existent right now. That financial burden falls disproportionately on women, who statistically earn less and are more likely to be managing household health decisions alone after widowhood.